Medite Cancer Diagnostics (MDIT) Price & Analysis

5 Followers

MDIT Stock Chart & Stats

$0.01

$0.00(0.00%)

At close: Jan 27 4:00 PM EST

$0.01

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.01 - $0.01

Previous CloseN/A

Volume10.00

Average Volume (3M)1.92K

Market Cap

$8.62K

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta-526.35

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding86,196,700

10 Day Avg. Volume1,918

30 Day Avg. Volume1,918

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

MDIT FAQ

What was Medite Cancer Diagnostics Inc’s price range in the past 12 months?

Medite Cancer Diagnostics Inc lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.

What is Medite Cancer Diagnostics Inc’s market cap?

Medite Cancer Diagnostics Inc’s market cap is $8.62K.

When is Medite Cancer Diagnostics Inc’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Medite Cancer Diagnostics Inc’s earnings last quarter?

Medite Cancer Diagnostics Inc released its earnings results on Aug 14, 2017. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.06.

Is Medite Cancer Diagnostics Inc overvalued?

According to Wall Street analysts Medite Cancer Diagnostics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medite Cancer Diagnostics Inc pay dividends?

Medite Cancer Diagnostics Inc does not currently pay dividends.

What is Medite Cancer Diagnostics Inc’s EPS estimate?

Medite Cancer Diagnostics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medite Cancer Diagnostics Inc have?

Medite Cancer Diagnostics Inc has 86,196,700 shares outstanding.

What happened to Medite Cancer Diagnostics Inc’s price movement after its last earnings report?

Medite Cancer Diagnostics Inc reported an EPS of -$0.06 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.

Which hedge fund is a major shareholder of Medite Cancer Diagnostics Inc?

Currently, no hedge funds are holding shares in MDIT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medite Cancer Diagnostics Inc

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. Medite Cancer Diagnostics, Inc. is based in Orlando, Florida.